Use of IL13 promoter to express therapeutic genes (SJ-18-0042)

St. Jude Reference #SJ-18-0042


Researchers at St. Jude developed a method to enhance the function of adoptively transferred T cells in an activation dependent manner; to insert therapeutic genes into the IL13 gene locus, which is tightly controlled by T-cell activation. Classes of therapeutic genes that could be inserted include, but is not limited to:

  • Chimeric antigen receptors
  • Cytokines
  • Cytokine receptors
  • Chimeric cytokine receptors
  • Other switch receptors
  • Chemokines
  • Antibodies
  • Bispecific antibodies

While several systems have been developed to couple gene expression to T-cell activation, most of them use viral-encoded regulatory elements, which are complex. The advantage of this approach is that it uses an endogenous promoter, that is tightly controlled by T-cell activation; and could be applied to the broad range of T-cell therapies that are currently being developed.


Enhance adoptively transferred T cell, insert therapeutic genes into the IL13 gene locus, Chimeric antigen receptors, Cytokines, Cytokine receptors, Chimeric cytokine receptors, Other switch receptors, Chemokines, Antibodies, Bispecific antibodies

Granted patents or published applications

Related scientific references

Zelda Odé, Jose Condori, Nicolas Peterson, Sheng Zhou, and Giedre Krenciute, “CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.” Cancers 2020, 12(6), 1704;

Licensing opportunities

Please contact us if you are interested in licensing this technology. Contact:

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.